Integrin PSI domain has endogenous thiol-isomerase function.
Novel anti-β3 PSI antibodies inhibit PDI-like activity and platelet adhesion/aggregation, and have antithrombotic therapeutic potential.
Integrins are a large family of heterodimeric transmembrane receptors differentially expressed on almost all metazoan cells. Integrin β subunits contain a highly conserved plexin-semaphorin-integrin (PSI) domain. The CXXC motif, the active site of the protein-disulfide-isomerase (PDI) family, is expressed twice in this domain of all integrins across species. However, the role of the PSI domain in integrins and whether it contains thiol-isomerase activity have not been explored. Here, recombinant PSI domains of murine β3, and human β1 and β2 integrins were generated and their PDI-like activity was demonstrated by refolding of reduced/denatured RNase. We identified that both CXXC motifs of β3 integrin PSI domain are required to maintain its optimal PDI-like activity. Cysteine substitutions (C13A and C26A) of the CXXC motifs also significantly decreased the PDI-like activity of full-length human recombinant β3 subunit. We further developed mouse anti-mouse β3 PSI domain monoclonal antibodies (mAbs) that cross-react with human and other species. These mAbs inhibited αIIbβ3 PDI-like activity and its fibrinogen binding. Using single-molecular Biomembrane-Force-Probe assays, we demonstrated that inhibition of αIIbβ3 endogenous PDI-like activity reduced αIIbβ3-fibrinogen interaction, and these anti-PSI mAbs inhibited fibrinogen binding via different levels of both PDI-like activity-dependent and -independent mechanisms. Importantly, these mAbs inhibited murine/human platelet aggregation in vitro and ex vivo, and murine thrombus formation in vivo, without significantly affecting bleeding time or platelet count. Thus, the PSI domain is a potential regulator of integrin activation and a novel target for antithrombotic therapies. These findings may have broad implications for all integrin functions, and cell-cell and cell-matrix interactions.
Integrins are primary mediators of cell-matrix and cell-cell adhesion, and play key roles in diverse fundamental biological processes, including embryo development, cell migration and differentiation, tumorigenesis, inflammation and immune response, atherosclerosis, hemostasis, and thrombosis.1-3 The integrin αIIbβ3 is essential for platelet adhesion and aggregation during hemostasis,3-6 and defects in αIIbβ3 may cause severe hemorrhage.7,8 Conversely, inappropriate platelet and integrin αIIbβ3 activation (such as at sites of atherosclerotic plaque rupture) may lead to thrombosis and myocardial infarction or stroke, the leading causes of morbidity and mortality worldwide.9,10
To date, 24 distinct members of the heterodimeric integrin superfamily have been identified, assembled from 18 α and 8 β subunits.1 Integrins exist in several switchable conformations, ranging from a bent low-affinity state to an extended high-affinity ligand-binding state.2,3 These conformational changes are regulated by their extracellular regions, transmembrane domains, and cytoplasmic tails,11-16 and by the bidirectional “inside-out” and “outside-in” signals, which regulate cell function.1,2,17-19
Although significant progress has been made to understand integrin biology, the biochemical basis of the allosteric movements and mechanisms of integrin activation remain to be further elucidated. It has been suggested that cysteine-derived thiol/disulfide groups of the β subunit are implicated in the conformational rearrangements.11,12,20,21 Disruption of disulfide bonds in the plexin-semaphorin-integrin (PSI), epidermal-growth-factor (EGF), and β-tail domains affect activation states of αIIbβ3.22-24 Disulfide bond remodeling in a physiologic context is mediated primarily by thiol-isomerases, such as protein-disulfide-isomerase (PDI), ERp5, and ERp57.25-27 This oxidoreductase activity is derived from active CXXC thioredoxin motifs. Through both intra- and intermolecular disulfide bond exchanges, these thiol-isomerases play a critical role in the post-translational modification and stabilization of newly synthesized proteins as well as maintenance of their structure and biological functions.18,21 It has been observed that thiol-isomerases secreted to the platelet surface after platelet activation play a role in the activation of αIIbβ3.28-33 Interestingly, endogenous thiol-isomerase (PDI-like) activity of αIIbβ3 has also been reported,34 though the exact origin of this endogenous enzymatic activity and its role in integrin conformational switches have yet to be uncovered.
The PSI domain, a 54-amino-acid sequence located near the N-terminus of the β subunit, is highly conserved across the integrin family and species, suggesting an essential role in integrin function. The location of this domain, at the “knee” region of the integrin in association with the hybrid domain, may be particularly significant during integrin conformational changes.11,35-37 The functionality of the PSI domain to β3 integrin has been alluded to in studies in which a polymorphism at residue 33 may induce generation of alloantibodies that cause thrombocytopenias and bleeding disorders.38,39 This polymorphism predisposes to an increased risk of cardiovascular disease.40 Interestingly, the PSI domain contains 7 cysteine residues, which have been implicated in restraining β2-integrin activation.41,42 Furthermore, substitution of residue Cys435, which abolishes the covalent link to Cys13 in the PSI domain,41 resulted in a constitutively active, ligand-binding conformation of αIIbβ3.24 However, to date the precise role of the PSI domain in integrins, along with its 7 cysteines residues, is largely unknown.
In the present study, we demonstrated that integrin PSI domain has endogenous thiol-isomerase activity. We developed β3 PSI domain–specific mouse anti-mouse monoclonal antibodies (mAbs), which cross-react with platelets from humans and other species tested. These mAbs inhibited the thiol-isomerase activity of αIIbβ3 and αIIbβ3-fibrinogen interaction and, importantly, inhibited platelet adhesion/aggregation in vitro and thrombus formation in murine models without significantly affecting bleeding time or platelet count. These findings reveal the potential of β3 PSI domain as a novel therapeutic target for the treatment of thrombotic diseases. Because the PSI domain is highly conserved across the integrin family and different species, this discovery may significantly advance our understanding of cell-cell and cell-matrix interactions, as well as provide insights into multiple human diseases and future therapies.
All animal studies were approved by the Animal Care Committee, and all experimental procedures using human blood samples were approved by the Research Ethics Board, St. Michael’s Hospital, Toronto, Ontario, Canada.
Cloning and expression of PSI domain recombinant proteins of murine β3, human β1, and β2 integrins
Plasmids coding for glutathione-S-transferase (GST)-murine β3 PSI domain and its mutants were transformed into Escherichia coli BL21 (DE3). The mutants were generated by mutating cysteines in CXXC motifs: C13S/C16S (mutant 1) or C23S/C26S (mutant 2), or in both C13S/C16S/C23S/C26S (double-mutant [DM]). The GST-fusion proteins were purified with a GSTrap column (GE Healthcare, QC, Canada).43 Human β1- and β2-integrin PSI domain recombinant proteins (rPSI) were generated by inserting respective cDNA fragments into the same pGEX-4T-1 vectors (Thermo Scientific) for expression.
Cloning and expression of full-length human β3-integrin recombinant proteins
Plasmid coding for full-length human β3-integrin subunits was subcloned into a modified pEF-IRES-puro vector that fused to C-terminal segments containing 6×His tag. Full-length human β3 plasmids were subjected to site-directed mutagenesis for cysteine substitutions (C13A and C26A in β3 PSI domain). Constructs were transfected into HEK 293 cells and proteins were purified as previously described.44
Thiol-isomerase function assay
Thiol-isomerase activity was measured as previously described,34 with minor modifications. Briefly, reduced/denatured RNase (rdRNase; 1-10 µg) was incubated with PDI or the PSI recombinant proteins (± preincubation with anti-PSI mAb, bacitracin or 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) for 2 hours at room temperature, or the mutants in 0.1M Tris-HCl, pH 7.4, containing 1 mM EDTA, overnight at room temperature. Then cytidine 2’,3′-cyclic monophosphate (0.1 mg/mL in 0.1 M 4-morpholinepropanesulfonic acid) was added and absorbance was measured at 284 nm.
Incorporation of Na-(3-maleimidylpropionyl)-biocytin into rdRNase
The Na-(3-maleimidylpropionyl)-biocytin (MPB) incorporation was performed as previously described.45 Briefly, the wild-type or double-mutant full-length β3 (0.50 µM) was incubated with rdRNase (2 µg/mL) followed by labeling MPB (100 µM) for 30 minutes at room temperature. All reactions were performed in 20 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 0.14 M NaCl buffer, pH 7.4. The biotinylated proteins were detected by western blotting with streptavidin–horseradish peroxidase (HRP).
Monoclonal antibody generation and characterization
Biomembrane-Force-Probe detection of fibrinogen-αIIbβ3 integrin interactions
Biomembrane-Force-Probe (BFP) was performed as previously described.48,49 Briefly, the target (αIIbβ3-bearing bead) and the probe (fibrinogen-bearing bead) were repeatedly brought into contact with a ∼15 pN compressive force for a known contact time (tc) (0.1-5 s for adhesion frequency assay) that allowed for bond formation, and then retracted for adhesion detection. Adhesion and nonadhesion events were enumerated to calculate an adhesion frequency in 50 cycles for each probe-target pair. Three to five probe-target pairs were measured to render an average adhesion frequency (Pa) at each tc. The two-dimensional (2D) effective on-rate (mrmlAckon) and 2D off-rate (koff) can be derived by fitting the Pa vs tc curve with a previously established model, where mr and ml are the surface densities of receptors and ligands, respectively, which are constants in all BFP experiments given that the same batch of integrin and fibrinogen beads were used.50 Ac is the contact area of the target and probe beads. kon is the 2D on-rate. The 2D effective affinity (mrmlAcKa) is calculated as mrmlAckon/koff.
In vitro platelet aggregation and ex vivo perfusion chamber assays
Platelet aggregometry51,52 and perfusion chamber assays53-55 were performed as previously described, and as detailed in the supplemental Methods, available on the Blood Web site. Platelet aggregation was induced by different agonists as indicated. For the perfusion chamber assay, heparinized, fluorescently labeled human or murine whole blood was perfused over a collagen-coated surface at high or low shear rates.
In vivo thrombosis models
The laser-induced intravital microscopy thrombosis model was performed as previously described.52,54-56 Dynamic accumulation of fluorescently labeled platelets within the growing thrombi was captured and analyzed. The FeCl3 (5%)–injured carotid artery thrombosis model was also performed.53,57 The blood flow was monitored by a Doppler flow probe and the time to the cessation of the blood flow was recorded as occlusion time.
Tail bleeding time and platelet count assays
Data are presented as mean ± standard error of the mean (SEM). Statistical significance was assessed by unpaired or paired, two-tailed Student t test and one-way analysis of variance followed by Bonferroni's multiple comparisons test.
Additional materials and methods can be found in the supplemental Data.
Integrin PSI domain has endogenous thiol-isomerase activity
Through analysis of the amino acid sequences of β3 integrin from various species, 2 CXXC motifs were found within the PSI domain. Interestingly, these CXXC sites are not only 100% conserved among different species, but also conserved in all β-integrin subunits. To determine whether integrin PSI domain has endogenous thiol-isomerase function, we generated recombinant murine β3 PSI domain protein (rPSI), as well as human integrin-β1 and -β2 rPSI. Using a reduced/denatured RNase assay, we demonstrated that murine β3 rPSI possesses concentration-dependent thiol-isomerase function, and that this activity was conserved in both human β1 and β2 rPSI (Figure 1A). Similar results were observed in an alternative thiol-isomerase activity (insulin turbidity) assay (supplemental Figure 1A). Notably, we found that the enzymatic activity of β3 rPSI was weaker than PDI (Figure 1B), which may represent its suboptimal structure and enzymatic activity in the recombinant protein.
We found that bacitracin, a universal thiol-isomerase inhibitor, dose-dependently inhibited PDI-like function in rPSI (Figure 1C), and in purified αIIbβ3 integrin (supplemental Figure 1B). Furthermore, an alternative thiol-isomerase inhibitor, DTNB, also inhibited the thiol-isomerase activity of murine β3 rPSI (Figure 1D). To exclude the possibility of protease activity derived from bacitracin contaminants affecting our observations, we demonstrated that the thiol-isomerase inhibitory function of bacitracin was preserved in the presence of a protease inhibitor cocktail (Figure 1E and supplemental Figure 1C).
Both CXXC motifs are required for optimal thiol-isomerase activity of integrin PSI domain and full-length β3 integrin
We first generated 3 mutant murine β3 rPSI proteins lacking specific cysteine residues. A mutation of cysteines in either of the CXXC motifs—C13S/C16S (mutant 1) or C23S/C26S (mutant 2) (Figure 1F)—markedly decreased the thiol-isomerase function (Figure 1G). In the DM, thiol-isomerase activity was completely abolished (Figure 1G). To further assess the significance of the CXXC motifs in the whole integrin β subunit, we generated full-length human-β3-subunit recombinant protein in which both CXXC motifs of the PSI domain were mutated (C13A and C26A). We found that the thiol-isomerase activity of this mutated β3 subunit was significantly decreased (Figure 1H). To confirm the thiol-isomerase function of β3 PSI, we measured the incorporation of MPB into rdRNase to directly demonstrate disulfide bond shuffling/exchange. Our data showed that there was significantly less MPB incorporated into rdRNase after incubation with wild-type, full-length β3 recombinant protein, compared with the DM (C13A/C26A) (Figure 1Ii). MPB incorporation into rdRNase in the presence of the DM was less than rdRNase alone, indicating that thiol-isomerase activity is present in other domains. Furthermore, we confirmed that recombinant human β3 PSI catalyzed the formation of new disulfide bonds and decreased MPB incorporation in rdRNase (Figure 1Iii). These findings clearly demonstrated that the PSI domain and other domains of β3 integrin possess thiol-isomerase activity.
Thiol-isomerase inhibitors decreased ligand binding to purified αIIbβ3 integrin
To elucidate whether endogenous thiol-isomerase activity affects integrin activation and ligand binding affinity, we examined the effects of bacitracin on the binding of fibrinogen and PAC-1 (a mAb that recognizes active human αIIbβ3 integrin) to purified human platelet β3 integrins, in a cell-free enzyme-linked immunosorbent assay (ELISA). We found that bacitracin significantly decreased fibrinogen and PAC-1 binding to activated human β3 integrin (Figure 2A-B), and this effect is not caused by the direct interaction between bacitracin and fibrinogen or PAC-1 because no binding signal was observed in an ELISA with bacitracin-coated wells (supplemental Figure 1D). These data are consistent with earlier reports in β3 and other integrins,32,33,61 demonstrating that endogenous PDI-like activity of β3 integrin is important for integrin conformational changes, leading to integrin activation and ligand binding.
Anti-β3 PSI monoclonal antibodies bind specifically to β3 integrin PSI domain and inhibit its PDI-like activity
To further examine the role of the PSI domain in integrins, particularly β3 integrin in relation to its role in hemostasis and thrombosis, we generated 4 unique mouse anti-mouse mAbs against the PSI domain of β3 integrin: PSI A1, PSI B1, PSI C1, and PSI E1. Using flow cytometry, we demonstrated that these antibodies bound to wild-type murine platelets, along with human, porcine, and rabbit platelets tested, but did not bind to murine β3−/− platelets (Figure 3A). These data indicate the specificity of the mAbs for β3 integrin and excluded the prospect of mAbs binding to other integrin β-subunits (eg, α2β1, α5β1, α6β1, α8β1 integrins) or other CXXC motif-containing proteins expressed on the platelet surface. Binding of the anti-PSI domain mAbs to human platelets was blocked by murine β3 rPSI, further confirming the specificity of the anti-PSI mAbs for the integrin PSI domain (supplemental Figure 2). Western blotting and immunoprecipitation demonstrated that these mAbs bound only to the β3 PSI domain but did not bind to other domains in the cysteine-rich region (CRR) of the β3-subunit (Figure 3B-C), ERp57, or β2 integrins (supplemental Figure 3). We also demonstrate that the mAbs do not cross-react with PDI or fibrinogen, using ELISA assay (Figure 3D-E). Because our mAbs can cross-react with β3 PSI domain from other species, these novel anti-PSI mAbs will be useful for animal models (eg, pigs, mice, rabbits) of different human diseases, including cardiovascular diseases.
To further characterize these anti-PSI mAbs and their epitopes, we performed competitive binding assays using rPSI or mutants (mutant 1 [C13S/C16S], mutant 2 [C23S/C26S], or the DM). We demonstrated that neither mutant 1 nor the DM inhibited binding of our anti-PSI mAbs to platelets (supplemental Figure 4). Conversely, mutant 2 significantly decreased the binding of PSI A1, PSI C1, and PSI E1, to levels almost comparable with nonmutated rPSI (supplemental Figure 4i,iii,iv). These results suggest that the presence of an intact C13XXC16 motif is critical for these 3 mAbs to bind to the PSI domain of αIIbβ3 on platelets. In the case of PSI B1, neither mutant 1, mutant 2, nor the DM had any significant effect on its binding to platelets (supplemental Figure 4ii). These data demonstrated that PSI B1 binds to β3 PSI domain depending on both CXXC motifs, suggesting a unique epitope for this antibody.
To investigate the effects of our anti-PSI mAbs on the thiol-isomerase activity of the β3 PSI domain, murine β3 rPSI was incubated with anti-PSI mAbs, then incubated with rdRNase overnight and, subsequently, RNase refolding was measured. We found that mAbs PSI B1 and PSI E1 abrogated PDI-like function of the PSI domain (Figure 3F). MAbs PSI A1 and PSI C1 reduced the thiol-isomerase activity of murine β3 rPSI, albeit to a lesser extent (Figure 3F). Consistently, both PSI B1 and PSI E1 strongly inhibited the thiol-isomerase activity of purified human native β3 integrin, and PSI A1 and PSI C1 significantly (but to a lesser extent) reduced this activity (Figure 3G). Our mAbs had no effect on the thiol-isomerase activity of CRR recombinant protein, indicating that our mAbs do not cross-react with other CXXC containing proteins (Figure 3H-I). These anti-PSI mAbs did not inhibit the thiol-isomerase activity of β1 or β2 rPSI (data not shown), further demonstrating their specificity for β3 PSI domain.
Anti-PSI mAbs significantly inhibited fibrinogen binding to αIIbβ3 in single-molecular BFP assays
To determine whether our anti-PSI mAbs affected fibrinogen binding to αIIbβ3, we used the BFP assay. This allowed us to detect fibrinogen-αIIbβ3 interactions and the binding force. We first showed that bacitracin and DTNB inhibited fibrinogen binding, which is consistent with our ELISA data (Figure 2A) and suggests that the endogenous αIIbβ3 PDI-like function is important for its ligand binding. We also found that these anti-PSI mAbs significantly inhibited αIIbβ3-fibrinogen interactions (Figure 4A).
To elucidate whether the decreased fibrinogen binding is caused by the inhibition of thiol-isomerase activity or a direct effect on αIIbβ3 conformational changes, we used bacitracin and DTNB, in combination with our anti-PSI mAbs in the BFP assays. We found that mAbs (PSI A1, PSI C1, or PSI E1) in combination with thiol-isomerase inhibitors (bacitracin or DTNB) decreased fibrinogen binding to αIIbβ3 more than either mAbs or thiol-isomerase inhibitors alone (Figure 4Bi,ii,iv,v). These data suggested that both inhibition of thiol-isomerase activity and mAb-blocked conformational changes synergistically attenuated the fibrinogen binding, and mAbs can further decrease αIIbβ3-fibrinogen binding beyond the thiol-isomerase activity (ie, steric hindrance of αIIbβ3-fibrinogen binding).
The mAbs PSI B1 and PSI E1 have significantly stronger anti–thiol-isomerase activity than PSI A1 and PSI C1 (Figure 3F-G); consistently, they have stronger inhibitory effect on αIIbβ3-fibrinogen interaction (Figure 4ABiii,v), suggesting that anti–thiol-isomerase activity partially contributed to their inhibitory effect. Interestingly, unlike PSI E1 as well as PSI A1 and PSI C1, the addition of bacitracin/DTNB did not further enhance the inhibitory effect of PSI B1 (Figure 4Biii), suggesting that PSI B1 binding not only blocks thiol-isomerase derived from the PSI domain itself but likely also inhibits the thiol-isomerase activities of other domains via intramolecular interactions. These data suggest that our anti-PSI mAbs exert their inhibitory effects via both thiol-isomerase activity–dependent and –independent mechanisms (ie, steric hindrance).
Anti-β3 PSI mAbs inhibited murine and human platelet aggregation in vitro and thrombus formation ex vivo
We performed studies to assess the role of anti-β3 PSI domain mAbs in platelet function. We found that platelet aggregation in both murine and human platelet-rich plasma (PRP) or gel-filtered platelets was significantly attenuated by all 4 anti-PSI mAbs (PSI A1, PSI B1, PSI C1, and PSI E1) after stimulation with various agonists including adenosine diphosphate (ADP), collagen, thrombin, and thrombin receptor–activating peptide (TRAP) (Figure 5A-D). We observed that the inhibitory effect of these anti-PSI mAbs was not dependent on FcγRII because no significant difference was observed in the absence or presence of the Fcγ receptor blocker, IV.3. We also did not find a significant difference (supplemental Figure 5) between phosphate-buffered saline (PBS) and IgG isotype control.
A perfusion chamber thrombosis model was used to evaluate whether anti-PSI mAbs affect thrombus formation under flow conditions. After perfusion over a collagen-coated surface, anti–PSI mAb pretreatment of murine blood dramatically inhibited platelet adhesion, aggregation, and thrombus growth at both high (1800s−1) and low (300s−1) shear (Figure 6A-D). Similar results were also observed with human blood at both high (1200s−1) and low (300s−1) shear (Figure 6E-H). Thus, these in vitro and ex vivo experiments clearly demonstrated that anti-PSI mAbs targeting the β3 PSI domain are significant inhibitors of thrombosis.
Anti-β3 PSI mAbs inhibited thrombosis in both small and large murine vessels in vivo
We used a laser-injury cremaster arteriole intravital microscopy model to quantitatively examine the effects of our anti-PSI mAbs on thrombosis. Consistent with our in vitro and ex vivo data, IV infusion of our anti-PSI mAbs (but not PBS or isotype control) markedly inhibited thrombosis (Figure 7A-B and supplemental Figure 6). To test the antithrombotic effect in large arteries, a carotid artery thrombosis model was used and vessel occlusion time after FeCl3 injury was also significantly postponed after treatment with a representative anti-PSI domain mAb, PSI C1 (Figure 7C). We confirmed that this observed inhibition of thrombosis and delayed vessel occlusion was not caused by the anti-PSI mAbs inducing platelet clearance or thrombocytopenia (Figure 7D).
Anti-β3 PSI mAbs did not significantly affect bleeding time and platelet count
Injection of effective dose (5 µg/mouse) of these anti-PSI antibodies did not prolong bleeding time, as evaluated by surgical tail transection (Figure 7E). Importantly, we also did not find a significant decreased platelet count at 40 minutes or 24 hours post-injection, which is markedly different from other anti-β3 integrin antibodies (supplemental Figure 7). These data suggest that these anti-PSI mAbs may have the potential to be developed as safe and effective antithrombotic agents.
In this study, we have clearly demonstrated that integrin-β3 PSI domain contains endogenous thiol-isomerase activity, which can be inhibited by bacitracin, DTNB, and our anti–β3 PSI mAbs. We have also shown that, consistent with the highly conserved nature of the amino acid sequence of the integrin PSI domain, this endogenous isomerase function is conserved across different species and integrin-β subunits. We have demonstrated that mutation of the CXXC motifs of the β3 PSI domain abolishes the thiol-isomerase activity of the PSI domain, as well as markedly decreases the thiol-isomerase activity of the entire β3 subunit. Using ELISA and the single-molecular technique BFP, we clearly showed that inhibition of the endogenous PDI-like function significantly reduced fibrinogen binding to αIIbβ3. Furthermore, we identified the PSI domain as a novel target for antithrombotic therapy because our newly developed anti-PSI mAbs inhibit the thiol-isomerase activity of β3 PSI domain, block fibrinogen binding to αIIbβ3, and abrogate platelet adhesion, aggregation, and thrombus formation in vitro and in both arterioles and larger arteries in vivo.
There are redox-active CXXC motifs present in other domains in the cysteine-rich region of integrin-β subunits such as the hybrid domain and the EGF domains. However, in the current study, we demonstrated that our anti-PSI mAbs specifically recognize β3 PSI domain, although their sensitivities to the mutations of PSI domain CXXC motif vary (supplemental Figure 4). These mAbs do not recognize other regions in β3 integrins, different integrins on platelets or leukocytes, or thiol-isomerases (PDI or ERp57) tested (Figure 3 and supplemental Figure 3). Therefore, the effect of these mAbs is attributed to their specific interactions with β3 PSI domain. The following information suggests that their anti–thiol-isomerase function is part of their effect on αIIbβ3. These include: (1) inhibition of endogenous thiol-isomerase activity by bacitracin or DTNB decreased the binding of fibrinogen or PAC-1 to αIIbβ3 (Figure 2A-B and Figure 4A-B); (2) the thiol-isomerase function of PSI domain is an important part of the enzymatic activity of the entire β3 subunit (Figure 1H-I,) that can be inhibited by these mAbs, which is consistent with the antiplatelet effects of these mAbs; and (3) the stronger the anti–thiol-isomerase activities by these mAbs, the stronger the inhibitory effect on αIIbβ3-fibrinogen binding in the pure BFP assays (Figure 4A-B). However, these anti-PSI mAbs can further inhibit αIIbβ3-fibrinogen interaction in the presence of sufficient concentrations of bacitracin or DTNB (Figure 4A-B), suggesting that these mAbs can also affect αIIbβ3 conformation beyond the thiol-isomerase activity (ie, both thiol-isomerase activity-dependent and -independent [steric hindrance] pathways).
It has been shown that disruption of disulfide bonds in the β3 PSI domain may affect its interaction with EGF domains and affect integrin functionality.23,24 Our BFP data for PSI B1 also suggest that completely or severely abolished thiol-isomerase function in PSI domain may affect the PDI-like activities in other regions (Figure 4A-B). Therefore, the thiol-isomerase activity of the PSI domain may be critical in the regulation of intramolecular interactions (eg, the hybrid and EGF domains), at the knee region of the integrin controlling the “swing-out” mechanism involved in integrin activation. This enzymatic activity may also be a key regulator of intermolecular interactions between integrins and integrin-associated proteins, along with other proteins present on the platelet surface, including thiol-isomerases and coagulation factors.30,62 Furthermore, this PSI domain thiol-isomerase activity leading to integrin conformational changes may induce intraplatelet signaling cascades triggering the secretion of additional platelet thiol-isomerases and enhancing platelet activation and thrombus formation.
PDI inhibitors have been proposed as a potential novel class of antithrombotics.63 However, because of the widespread distribution of PDI in the body, such therapies may result in off-target effects.64,65 Previous studies have shown that antibodies against PDI can cross-react with other PDI-like proteins, such as ERp5730 ; however, our anti-β3 PSI mAbs, interacting specifically with the β3 PSI domain, are likely able to reduce the clinical side effects. Furthermore, in our mouse models, treatment with the anti-PSI mAbs did not cause significant platelet clearance compared with other mAbs targeting integrin β3, and did not significantly prolong bleeding times. Notably, thrombosis is a complex multifactorial process, involving various cell types, including leukocytes and endothelial cells.5,6,66 Such cells also express integrins, and targeting the PSI domain of other β subunits may also have antithrombotic potential.
In addition to thrombosis, integrins are required for mediating interactions between almost all cells and their extracellular matrix components and are thus implicated in a diverse range of pathologic conditions such as tumorigenesis and metastasis, inflammation, atherosclerosis, and the entire process of thrombosis and macrophage-platelet interactions/embolus clearance.67-72 Targeting integrins is widely recognized and accepted as a potential therapy; however, to date, only a very limited number of integrin antagonists have achieved pharmacologic approval.73,74 Therefore, revealing the role of integrin PSI domains may not only be a considerable advance in the treatment of platelet-derived cardiovascular diseases but could also be a significant contribution to the general cell biology field and facilitate the exploitation of integrins as therapeutic targets for a wide range of conditions.
In summary, we have revealed the endogenous thiol-isomerase activity of the highly conserved PSI domain of the integrin family and uncovered a role for PSI domain in integrin activation and subsequent platelet function. Our novel mAbs inhibited this PDI-like activity of the PSI domain of β3 integrin, as well as platelet aggregation and thrombus formation. Importantly, these processes were inhibited without significantly increasing platelet clearance and prolonging bleeding times. These findings not only demonstrate the antithrombotic therapeutic potential of the anti-β3 PSI domain mAbs, but also further elucidate the complex mechanisms of integrin activation. Because the CXXC motifs of the PSI domain are completely conserved across all integrin-β subunits and species, our discoveries should also have broad implications for the greater cell biology field, and may advance the treatment of multiple human diseases.
Presented in part orally at the 2012 annual meeting of the American Society of Hematology; 2013 Congress of International Society of Thrombosis and Haemostasis; Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions 2014; Platelets 2014–the 8th International Symposium; and highlights in plenary of 2015 Congress of International Society of Thrombosis and Haemostasis.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
The authors thank Barry S. Coller (The Rockefeller University, New York) and Bruce Furie (Beth Israel Deaconess Medical Center, Massachusetts) for their valuable comments during this manuscript preparation, F. Patrick Ross (The Ohio State University, Ohio) for the generous gift of murine β3 integrin cDNA, and Reid C. Gallant and Alexandra H. Marshall (Keenan Research Center, St. Michael’s Hospital) for editing the manuscript.
This work was supported by the Canadian Institutes of Health Research (MOP# 97918, MOP# 119540), Heart and Stroke Foundation of Canada (Ontario), and Canadian Foundation for Innovation; a National Natural Science Foundation of China grant (No. 31371163); and Fundamental Research Funds for the Shenzhen of China (GJHZ201404221516216). N.C. is a recipient of The Canadian Blood Services Postdoctoral Fellowship; M.X. is a recipient of State Scholarship Fund from China Scholarship Council and Ontario Trillium Scholarship, Canada; Y.W. is a recipient of Graduate Fellowship from Canadian Blood Services and Meredith & Malcolm Silver Scholarship in Cardiovascular Studies; X.R.X. is a recipient of the Heart and Stroke/Richard Lewar Centre of Excellence Studentship award and Meredith & Malcolm Silver Scholarship in Cardiovascular Studies; and Y.C. and C.Z. were supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (AI-044902).
Contribution: G.Z. planned and carried out experiments, analyzed data, and prepared manuscript; Q.Z. and E.C.R. carried out experiments, analyzed data, and prepared manuscript; N.C. carried out experiments, analyzed data, and contributed to preparation of the manuscript; Y.C. carried out the BFP experiments and analyzed data; X.R.X. carried out experiments, analyzed data, and contributed to preparation of the manuscript; M.X., Y.W., Y.H., L.M., Y.L., M.R., T.N.P.-P., C.L., T.W.S., X.L., and R.A. carried out experiments; P.C. designed and prepared recombinant proteins and mutants; C.Z. provided key equipment and analyzed data; J.A.W. analyzed data and contributed to preparation of the manuscript; R.O.H. provided the key β3−/− mice and valuable comments during the manuscript preparation; J.F. provided key equipment, analyzed data, and contributed to preparation of manuscript; and H.N. supervised the research, analyzed data, and prepared the manuscript.
Conflict-of-interest disclosure: Integrin β3 anti-PSI monoclonal antibodies are patented in the United States, Canada, and Europe (United States Patent Application No. 12/082 686; Canadian Patent application No. 2 628 900; European Patent Application No. 08153880.3).
Correspondence: Qing Zhang, Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, P.R. China; e-mail: firstname.lastname@example.org; and Heyu Ni, Canadian Blood Services Centre for Innovation, and Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Room 421, LKSKI-Keenan Research Centre, 209 Victoria St, Toronto, ON M5B 1W8, Canada; e-mail: email@example.com.
G.Z., Q.Z., and E.C.R. contributed equally to this work.